New hope for rare, Tough-to-Treat lung cancer
NCT ID NCT07153055
Summary
This study is testing the safety and effectiveness of combining two drugs, lurbinectedin and osimertinib, for a rare and aggressive type of lung cancer called transformed small cell lung cancer. It will involve about 16 adults whose cancer started as one type and changed into this more difficult-to-treat form. The main goals are to find the safest dose and see if the combination can help control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.